New channels for bio-engineering and research
The Covid-19 pandemic has brought the pharma and biotech industry sharply into focus, especially with the race to develop safe, effective vaccines.
Anton Paar instruments are used for in-depth study of biotechnological samples to understand complex processes and interactions. They perform relatively ‘simple’ tasks such as determining the concentration of substances at different temperatures, as well as ‘complex’ ones, like characterizing nanostructures and their behavior under different conditions – delivering information on the behavior of materials in fields such as applied immunology, molecular engineering, and genetic engineering.
The instruments are opening up new channels for engineering and research on biomaterials, membranes, and medical samples requiring high-precision tools that are reliable and intuitive to use. They make possible the pioneering investigation of chemical processes, the behavior of particles, mechanical or elastic behavior or permeability, and more.
And they’re helping pharma and biotech companies deliver safe, top-quality products in a highly regulated sector, compliant with 21 CFR Part 11, FDA regulations and diverse Pharmacopoeia, and in accordance with ALCOA+ principles on data handling.
For 100 years, Anton Paar has combined high-precision technology with scientific curiosity and a thirst for research. Today, it is the global market leader in the fields of density and concentration measurement, rheometry and CO2 measurement. Many of the world’s leading companies – not just across beer, wine and soft drink production, but also in pharmaceuticals and cosmetics, and chocolate and cell phone display manufacturing – rely on the technical know-how and instruments of the Anton Paar Group.
Anton Paar GmbH has 45 sister companies and sales subsidiaries, as well as 50 sales partners, and operates in more than 110 countries around the world. "Talent, commitment and inner cohesion, in both successful and difficult times, have always distinguished us and our company,” says CEO Friedrich Santner. “With these attributes, we are confidently entering the second century of our history."
The non-profit Santner Private Foundation has owned the company since 2003. The foundation has two purposes: the promotion of non-profit science and research, and the prevention of drug addiction and the support of projects to combat addiction.